Potassium Chloride Extended Release Tablets
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Logistics Agency (DLA) Troop Support has awarded AvKARE, LLC a contract (SPE2D2-26-D-0001) for the supply of Potassium Chloride Extended Release Tablets. This award, valued at an estimated $39,510,148.75 over five years, ensures the provision of essential pharmaceutical products. The contract was awarded on March 19, 2026, following a reverse auction.
Scope of Work
This contract covers the supply of various Potassium Chloride ER tablets, including:
- Potassium Chloride ER 10 MEQ Tablets (100 and 500 count bottles)
- Potassium Chloride ER 20 MEQ Tablets (100 and 500 count bottles) Quantities are estimates and subject to FAR 52.216-21 requirements. Manufacturing and packaging locations are specified within the contract.
Contract & Timeline
- Contract Number: SPE2D2-26-D-0001
- Awarded To: AvKARE, LLC
- Total Award Amount: $39,510,148.75 (5-year estimate)
- Period of Performance: Implied 5 years based on total award and option years.
- Contract Type: Commercial Items
- Set-Aside: UNRESTRICTED (NAICS 325412, Size Standard 1300)
- Award Date: March 19, 2026
- Original Solicitation: SPE2D2-24-R-0013 (with numerous amendments)
Evaluation
The award resulted from a competitive process, including a Reverse Auction conducted on July 29, 2025, where AvKARE LLC submitted the lowest bid.
Additional Notes
The document incorporates by reference numerous Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) clauses. The acquisition is listed as UNRESTRICTED, but numerous small business set-aside clauses are incorporated by reference, indicating potential subcontracting opportunities. Appendix A lists current Pharmaceutical Prime Vendors as of the solicitation date.